Business Wire

KINAXIS

12.3.2024 12:01:32 CET | Business Wire | Press release

Share
Intelligent Not Artificial: The Momentum Behind AI Innovation at Kinaxis

Kinaxis (TSX:KXS), the global leader in supply chain orchestration, and a pioneer in artificial intelligence (AI) and machine learning (ML), has been laying the groundwork for continued success in the industry through a rapidly growing patent portfolio. Over the past five years, the company’s patent portfolio has grown by more than 500% and as of today, 55% of the portfolio is for AI and ML-based innovations.

The exponential growth comes as a direct result of significant investments in research and development as part of the company’s commitment to strengthen its leadership position as a trusted technology provider to chief supply chain officers globally. As part of a robust innovation program, Kinaxis continues rolling out a steady stream of AI- and ML-powered capabilities, which empower its 40,000 users to build the most intelligent supply chains on the planet.

Kinaxis uses AI innovation to drive better results while maintaining the speed and agility required to navigate modern supply chain challenges - by generating prescriptive recommendations, predicting and surfacing insights, automating processes and enhancing productivity through its platform. This human-centred approach puts people first, augmenting their capabilities to support faster and more informed decision making.

“Kinaxis has always been about making life easier for the people behind supply chains and the people they serve, and our patent portfolio is a strong indicator of our success innovating in this space,” said Chantal Bisson-Krol, vice president of AI & ML solutions at Kinaxis. “Our approach to innovating with AI/ML is no different. Our solutions are purpose-built, ensuring AI augments the people using it, so they can make decisions with more speed and accuracy. The recent AI patent growth we’ve seen demonstrates that this approach is working.”

“In an era where supply chains are increasingly complex and where agility, resilience, and sustainability are imperatives, the companies that best leverage AI/ML to enhance the capabilities of their supply chain teams will emerge as leaders,” said Tariq Farooq, former chief supply chain officer at Sanofi. “Kinaxis has a laser-like approach to pushing the boundaries of what’s possible and the growth of its AI/ML patent portfolio make it well-placed to support their client teams in their supply chain transformations.”

Pending and issued patents cover all aspects of Kinaxis technology, examples of which include:

  • Dynamic Demand Sensing patents that provide better understanding of how both internal (e.g. frequent price changes, new product introductions, changes to promotional plans) and external factors (e.g. weather, shifts in consumer behavior, local/national events) are influencing short- and long-term demand for their products.
  • Patents that significantly expedite the various tasks in a ML workflow, providing timely responses and insights for retail scale data.

Kinaxis’ AI-powered technology and patented concurrency technique allows companies to orchestrate their supply chain network end-to-end from strategic planning to last-mile delivery. Kinaxis technology helps companies supply the agricultural industry with 40% of the world’s tractors, helps keep more than 110,000,000,000 teeth clean each year, and ensures more than 35 million pets are fed nutritious meals each year.

To learn more about Kinaxis and how it is transforming the way AI is used in supply chains, please visit https://www.kinaxis.com/en/artificial-intelligence

About Kinaxis

Kinaxis is a global leader in modern supply chain management. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to orchestrate their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240312570571/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye